Leussink VI - Search Results

1

Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.

Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP. Kieseier BC, et al. Among authors: leussink vi. JAMA Neurol. 2013 Mar 1;70(3):390-3. doi: 10.1001/jamaneurol.2013.668. JAMA Neurol. 2013. PMID: 23599943

2

Immunomodulatory treatment strategies in multiple sclerosis.

Kieseier BC, Wiendl H, Leussink VI, Stüve O. Kieseier BC, et al. Among authors: leussink vi. J Neurol. 2008 Dec;255 Suppl 6:15-21. doi: 10.1007/s00415-008-6004-z. J Neurol. 2008. PMID: 19300955 Review.

3

Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of 'Chinese restaurant syndrome'.

Leussink VI, Hartung HP, Stüve O, Kieseier BC. Leussink VI, et al. J Neurol. 2016 May;263(5):1027-1028. doi: 10.1007/s00415-016-8110-7. Epub 2016 Apr 8. J Neurol. 2016. PMID: 27060083 No abstract available.

4

Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity.

Leussink VI, Lehmann HC, Meyer zu Hörste G, Hartung HP, Stüve O, Kieseier BC. Leussink VI, et al. J Neurol. 2008 Sep;255(9):1436-8. doi: 10.1007/s00415-008-0956-x. Epub 2008 Jul 17. J Neurol. 2008. PMID: 18685916 No abstract available.

5

Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.

Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC. Stüve O, et al. Among authors: leussink vi. Arch Neurol. 2009 Feb;66(2):259-61. doi: 10.1001/archneurol.2008.551. Arch Neurol. 2009. PMID: 19204165

6

Cladribine as a therapeutic option in multiple sclerosis.

Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP. Warnke C, et al. Among authors: leussink vi. Clin Immunol. 2012 Jan;142(1):68-75. doi: 10.1016/j.clim.2011.05.009. Epub 2011 Jun 1. Clin Immunol. 2012. PMID: 21733757 Review.

7

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.

Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC. Warnke C, et al. Among authors: leussink vi. Neurology. 2014 Dec 2;83(23):2153-7. doi: 10.1212/WNL.0000000000001049. Epub 2014 Oct 31. Neurology. 2014. PMID: 25361781 Clinical Trial.

8

Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Leussink VI, Hartung HP, Kieseier BC, Stettner M. Leussink VI, et al. Ther Adv Neurol Disord. 2016 Jul;9(4):336-43. doi: 10.1177/1756285616641583. Epub 2016 Apr 6. Ther Adv Neurol Disord. 2016. PMID: 27366241 Free PMC article. Review.

9

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy.

Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, MacKenzie CR, Warnke C, Feldt T, Lammerskitten A, Klotz L, Meuth S, Wiendl H, Hartung HP, Aktas O, Albrecht P. Graf J, et al. Among authors: leussink vi. Ann Clin Transl Neurol. 2017 Nov 24;4(12):909-914. doi: 10.1002/acn3.491. eCollection 2017 Dec. Ann Clin Transl Neurol. 2017. PMID: 29296620 Free PMC article.

10

Type III systemic allergic reaction to natalizumab.

Leussink VI, Lehmann HC, Hartung HP, Gold R, Kieseier BC. Leussink VI, et al. Arch Neurol. 2008 Jun;65(6):851-2; author reply 852. doi: 10.1001/archneur.65.6.851-b. Arch Neurol. 2008. PMID: 18541818 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters